BAU Journal - Health and Wellbeing
Volume 4 Issue 2
ISSN: 2617-1635

Article 3

April 2022

ASSESSMENT OF THE LEBANESE COMMUNITY PHARMACIST
KNOWLEDGE, PRACTICE AND BARRIERS REGARDING THE
PREVENTION OF OSTEOPOROSIS
Noura Issa Khram
Pharm D, Faculty of Pharmacy, Beirut Arab University, Beirut, Lebanon, norellaissah@gmail.com

Maha Aboul Ela
Professor, Department of Pharmaceutical Sciences, Faculty of Pharmacy, Beirut Arab University, Beirut,
Lebanon, mahaaboulela@bau.edu.lb

Mohamad Ali Hijazi
Assistant Professor, Department of Pharmaceutical Sciences, Faculty of Pharmacy, Beirut Arab University,
Beirut, Lebanon, m.hijazi@bau.edu.lb

Lama Soubra
Associate Professor, Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Beirut Arab
University, Beirut, Lebanon, l.soubra02@bau.edu.lb
Follow this and additional works at: https://digitalcommons.bau.edu.lb/hwbjournal
Part of the Architecture Commons, Business Commons, Life Sciences Commons, and the Medicine
and Health Sciences Commons

Recommended Citation
Khram, Noura Issa; Aboul Ela, Maha; Hijazi, Mohamad Ali; and Soubra, Lama (2022) "ASSESSMENT OF
THE LEBANESE COMMUNITY PHARMACIST KNOWLEDGE, PRACTICE AND BARRIERS REGARDING THE
PREVENTION OF OSTEOPOROSIS," BAU Journal - Health and Wellbeing: Vol. 4: Iss. 2, Article 3.
DOI: https://www.doi.org/10.54729/TJQN9288
Available at: https://digitalcommons.bau.edu.lb/hwbjournal/vol4/iss2/3

This Article is brought to you for free and open access by Digital Commons @ BAU. It has been accepted for
inclusion in BAU Journal - Health and Wellbeing by an authorized editor of Digital Commons @ BAU. For more
information, please contact ibtihal@bau.edu.lb.

ASSESSMENT OF THE LEBANESE COMMUNITY PHARMACIST KNOWLEDGE,
PRACTICE AND BARRIERS REGARDING THE PREVENTION OF OSTEOPOROSIS
Abstract
Osteoporosis is a silent skeletal disease that is often recognized when fractures occur as a result of
minimal trauma. Limited studies have assessed the degree of pharmacists’ involvement in osteoporosis
prevention, risk-assessment/screening and physician referrals. To assess the Lebanese community
pharmacists’ knowledge, practice and barriers regarding osteoporosis prevention. Secondary aim is to
assess the pharmacists’ ability to identify high-risk patients who should be referred for bone mineral
density (BMD) testing. A cross-sectional study was carried out in Beirut, Lebanon between September
and October 2020 using self-administered questionnaire. Pharmacists completed a multi-component
questionnaire that consisted of socio-demographic characteristics, practices, knowledge and barriers in
relation to osteoporosis prevention and high-risk identification. Frequencies and proportions were used to
describe the data. Simple and multiple linear regression analysis were used to examine the determinants
of knowledge in the study population. The majority of pharmacists were rarely/never involved in counseling
patients on osteoporosis risk factors (57.5%) and healthy lifestyle habits (62.5%) as well as engaging
in risk-assessment (63.1%), screening using Fracture Risk Assessment Tool (FRAX) (0%) and physician
referrals (sometimes-55.6%). In addition, pharmacists were also scarcely involved in reducing the risk
of falls (55.1-59.4%). Pharmacists were knowledgeable about osteoporosis prevention however had
important gaps in the diseases that increase osteoporosis risk as well as in FRAX tool, indications that
require BMD testing and increased risk of fall medications. Significant predictors of knowledge were
receiving postgraduate training on osteoporosis and earning the pharmacy degree from a university in
Lebanon. Barriers to providing osteoporosis services included lack of time, staff, space, patients’ interest
in prevention activities and limited inter-professional collaboration. The study findings provided important
insights on the practices, knowledge and barriers of pharmacists regarding osteoporosis prevention and
high-risk identification. Concerted efforts of multiple stakeholders are needed to promote the active role of
community pharmacists in order to reduce the risk of morbidity, mortality and health-care costs associated
with osteoporosis and related fractures.
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1. INTRODUCTION
Osteoporosis is a silent progressive skeletal disease that is often recognized when fractures
occur as a result of minimal trauma due to low bone mineral density (Tu et al., 2018). According
to the International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures
annually in adults over the age of 50 worldwide (IOF, 2020). As for the prevalence in the Middle
East region, specifically in Lebanon, a population-based study enrolled 432 elderly subjects from
Beirut area and identified a prevalence of 33.0% in women and 22.7% in men (Baddoura et al.,
2007). Hip fracture incidence rates for those over 50 years have been reported between 164 and
188/100 000 for females and between 88 and 107/100 000 for males per year. Moreover, total hip
fractures alone were estimated to cost around $10.2 million annually in year 2020 (El-Hajj
Fuleihan et al., 2011).
Primary osteoporosis is related to aging and gonadal hormone deficiency, while secondary
osteoporosis is caused by various drugs and/or diseases. Alcoholism, glucocorticoid use and
hypogonadism are more common in men. On the other hand, the most common secondary causes
in women were due to calcium metabolism disorders, hyperparathyroidism, hyperthyroidism,
Cushing’s disease, glucocorticoid and aromatase inhibitor use (Tu et al.; Gheita & Hammam,
2018). In the Middle East region, osteoporosis was also highly prevalent in rheumatoid arthritis
and diabetic patients with 46% in the Egyptian and 29.4-34% in the Saudi population (Gheita &
Hammam 2018). A Lebanese study also identified that 74.1% of the population took proton pump
inhibitors for an unsuitable duration, thus causing concern of increased fracture risk on long-term
use (Nawas et al., 2016).
Factors that increase the risk of osteoporosis are divided into two: non-modifiable and
modifiable. Non-modifiable risk factors include certain comorbidities, family history of
osteoporosis along with fracture in first degree relatives, advanced age, White or Asian race, female
gender and menopause. Modifiable risk factors include certain medications, leanness
(BMI<20kg/m2), physical inactivity, high caffeine intake, low calcium intake, vitamin D
deficiency, smoking and alcoholism (Camacho et al., 2020; Watts et al., 2012; Gel-H et al., 2007;
Ebeling et al., 2013).
Osteoporosis was once considered an inevitable consequence of aging, however now it is
eminently preventable. The first step in prevention is being aware of its risk factors along with
bone health optimization (Khosla & Hofbauer 2017). This includes weight control, physical
activity (particularly weight-bearing and muscle-strengthening exercises), limitation of alcohol
intake (≤2 drinks/day), smoking cessation, adequate calcium and vitamin D intake. The
recommended daily intake of calcium in women aged over 50 and men over 70 years is 1200 mg,
while 1000 mg is recommended to men aged between 50 and 70 years. Adequate calcium intake
accompanied by caffeine restriction (less than 1-2 servings/day with 8-12 ounces/serving) offsets
caffeine’s detrimental effect on the bone (Camacho et al., 2020; Watts et al., 2012; Gel-H et al.,
2007). On the other hand, insufficient dietary intake of calcium requires the need for calcium
supplementation. All calcium preparations, except calcium citrate, depend on gastric acid secretion
thus should be taken with food with a maximum of 500–600 mg of calcium per dose for optimal
absorption (Sozen et al., 2017).
In Middle-Eastern countries, more particularly Lebanon, vitamin D deficiency appeared to
be highly prevalent despite the abundance of sunshine. The reason was found to be multifactorial
such as inadequate sun exposure, wearing of veils, high body mass index and genetic factors. This
suggests the need for vitamin D supplementation (Chakhtoura et al., 2018; Gannage-Yared et al.,
2008; Medlej‐Hashim et al., 2015). Adults above 50 years require 1000-2000 IU/day to maintain
a desirable serum 25(OH)D level of 20 ng/ml (Chakhtoura et al., 2014). Additionally, reducing the
risk of falls is also essential, it can be achieved by implementing safety hazards at home along with
adjusting medications associated with high-risk of falls (e.g. psychotropic drugs) (Camacho et al.,
2020; Huang & Mallet 2016; Seppala et al., 2018).
Pharmacological therapies used for prevention include bisphosphonates, selective estrogen
receptor modulators (e.g. raloxifene) and estrogen replacement therapy (Camacho et al., 2020;
Chakhtoura et al., 2014). According to the Lebanese osteoporosis guidelines, definite indications
for BMD testing include patients above 65 years, presence of vertebral deformity or radiologic
evidence of low bone density, chronic use of glucocorticoids (>3-6 months) and the use of
aromatase inhibitors or androgen deprivation therapy. For all other indications, Fracture Risk
Assessment Tool (FRAX) should be used, it takes into account several risk factors such as age,
Published by Digital Commons @ BAU, 2022

1

BAU Journal - Health and Wellbeing, Vol. 4, Iss. 2 [2022], Art. 3

gender, race, body mass index, alcohol use, smoking history, prior personal or parental history of
fracture, use of glucocorticoids, secondary osteoporosis, rheumatoid arthritis, and femoral neck
BMD measurements to predict the 10-year probability of hip fracture and other major osteoporotic
fracture (MOF). Therefore, it acts as a gatekeeper identifying individuals who would be candidates
for BMD testing (if MOF risk estimates close to 10% ± 4% margin error ie.6-14%) or
pharmacological treatment (>14% and above age-specific threshold). BMD testing allows in the
early detection of osteoporosis before fractures occur and in providing prophylactic or therapeutic
treatment to high-risk patients (Chakhtoura et al., 2014).
According to literature, multiple population-based studies have evaluated the knowledge on
osteoporosis, the majority of which pointed at the need for further education (El-Tawab et al., 2016;
El Hage et al., 2019; Sayed-Hassan et al., 2013; Gayathripriya et al., 2017; Haq et al., 2015). Scarce
data on the other hand, have assessed osteoporosis knowledge among healthcare professionals.
Limited studies were also available assessing the degree of pharmacists’ involvement in
osteoporosis prevention, risk-assessment/screening and physician referrals. (Al-Musa et al., 2013;
Fogelman et al., 2016; Laliberté et al., 2013; Nik et al., 2016). Therefore, the aim of this study is
focused on the assessment of the Lebanese community pharmacists’ knowledge, practice and
barriers regarding the prevention of osteoporosis. Secondary aim is to assess the pharmacists’
ability to identify high-risk patients who should be referred for BMD testing.

2. METHODS
2.1 Study Design
This is a cross-sectional descriptive study conducted between September and October
2020 using self-administered questionnaire (hard-copy). Pharmacists practicing in
community pharmacies in Beirut were invited to fill the questionnaire with no reward in
return. The study was an observational one that respects the participant’s confidentiality and
autonomy. Accordingly, an exempt was issued from the institutional review board for being
a low-risk study.

2.2 Inclusion and Exclusion Criteria
Inclusions were Lebanese community pharmacists who were: (1) licensed to practice
by the Ministry of Public Health (MoPH), (2) registered in the Order of Pharmacists of
Lebanon (OPL) (3) working as pharmacy owner or an employee in the community pharmacy
and (4) have at least 1 year of work experience. Exclusions were: (1) pharmacists who do not
meet inclusion criteria, (2) pharmacy technicians and (3) pharmacists working in hospitals
and institutions.

2.3 Sample Size Calculation
The sampling unit for this study was the pharmacy. The number of community
pharmacies was obtained from the OPL website which indicated the presence of 235
pharmacies in Beirut. Sample size calculations using Raosoft® online calculator showed that
a total of 147 participants and above would be a representative sample size with a confidence
level of 95% and a margin errorof 5%.

2.4 Questionnaire Development and Data Collection
The questionnaire was written in English then translated to Arabic, the native language.
The first section included sociodemographic information such as age, gender, highest
educational level, whether the pharmacist received education/training related to
osteoporosis during his/her university years, employment status, years of work experience,
pharmacy location and the time period the pharmacy was open for. The second section
consisted of two parts, the first part assessed the practices of pharmacists related to providing
services with regards to osteoporosis prevention and high-risk identification, reducing the
risk of falls and medication counselling. The second part included Yes/No questions related
to the use of FRAX in current practice. The third section included barriers in providing
osteoporosis services (Laliberté et al., 2013; Nik et al., 2016; Khan et al., 2013). The last
section consisted of 14 questions that addressed the pharmacists’ knowledge on osteoporosis
risk factors, lifestyle modifications that improves bone health, therapies used in prevention,
indications for BMD testing and increased risk of fall medications (Gheita & Hammam,2018;
Nawas et al., 2016; Camacho et al., 2020; Huang & Mallet 2016; Seppala et al., 2018;
Chakhtoura et al., 2014; Al-Musa et al., 2013; Fogelman et al., 2016; Akande-Sholabi et al.,
https://digitalcommons.bau.edu.lb/hwbjournal/vol4/iss2/3
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2020;El-Tawab et al., 2016; El Hage et al., 2019; Sayed-Hassan et al., 2013; Gayathripriya
et al., 2017;Haq et al., 2015). The questionnaire was tested for appropriateness by several
experts and further adjustments were done after pilot testing with 10 pharmacists.

2.5 Data Analysis
The results were analyzed using Statistical Package for the Social Sciences (SPSS®)
version 23. Descriptive statistics was used to summarize the data of the study participants.
Additionally, for knowledge, a score was generated that corresponds to the sum of points of
questions answeredcorrectly. A score value of ‘1’ was given for correct answer and ‘0’ for
incorrect or ‘I do not know’ answer. Provided that the knowledge section consisted of 14
questions, with the last two questionswith a score out of ‘3’ and ‘4’, the knowledge score
ranged between ‘0’ and ‘19’, in which higher values of the score reflected better knowledge.
Simple and multiple linear regression analysis was used to investigate the correlation of
sociodemographic factors with knowledge. All results were considered statistically
significant when the p-value <0.05 with confidence interval of 95%.

3. RESULTS
One hundred sixty pharmacists participated in this study. The majority of the participants
were aged 40 years and below (67.5%), female respondents (61.2%) and employees (69.4%) at the
community pharmacy. As for the highest educational level attained, half were holders of a
Bachelor’s degree (50%), while the other half had achieved higher degrees: 23.1% a Pharm D
degree, 23.8% a Masters’ degree and 3.1% a PhD degree. Eighty-three percent achieved their
university education in Lebanon with 80.6% reported receiving enough information on
osteoporosis during their university years and 33.8% reported receiving post-graduate training on
osteoporosis. Forty-eight percent of the pharmacists had 1-7 years of work experience and majority
worked in a pharmacy that has been open for more than ten years (68.1%) (Refer to table 1).
Table 1: Demographic profile of the participants. (n=160)
Characteristic
Age range:
< 30 years
31 – 40 years
≥ 41 years
Gender:
Male
Female
Employment status:
Employee
Pharmacy owner
Highest educational qualification attained:
Bachelors
Masters
Pharm D
Ph.D.
University graduated from:
In Lebanon
Outside Lebanon
In your university years, did you have enough information
about osteoporosis?
Yes
No
Did you receive any postgraduate training on osteoporosis?
Yes
No
Years of work experience:
1 – 7 years
8 – 10 years
Above 10 years
How long has this pharmacy been opened for?
1 –7 years
8 – 10 years
Above 10 years

Published by Digital Commons @ BAU, 2022

Frequency (n)

Percentage (%)

66
42
52

41.3
26.2
32.5

62
98

38.8
61.2

111
49

69.4
30.6

80
38
37
5

50
23.8
23.1
3.1

133
27

83.1
16.9

129
31

80.6
19.4

54
106

33.8
66.2

77
26
57

48.1
16.3
35.6

33
18
109

20.6
11.3
68.1
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From the current practices, the majority of the pharmacists reported that they rarely/never
obtainpatient information to identify risk factors related to osteoporosis (63.1%), counsel patients
on osteoporosis risk factors (57.5%), lifestyle modifications to optimize bone health (62.5%),
advice on adequate daily calcium (58.2%) and vitamin D intake (66.3%-sometimes), review
medication profile to identify increased risk of fall patients (59.4%) and counsel on fall prevention
techniques(55.1%). Additionally, 55.6% of the pharmacists reported that they sometimes refer
high-risk patients to a doctor for BMD testing. On the other hand, the majority of the pharmacists
reported that they always/often counsel patients on proper way to take medication (84.4%), ensure
patient adherence (62.5%), check for drug or food interactions (64.4%) and take feedback for any
side effect experienced after taking osteoporotic medication (53.8%) (Refer to Fig. 1).

Fig.1: Current practice towards providing osteoporosis services among community pharmacists in Beirut.

As shown in Fig. 2, 80% of the pharmacists have not heard of Fracture Risk Assessment
Tool(FRAX) and 20% who have heard of the tool do not use it to assess patients who are at risk in
theirpractice.
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Fig.2: Current practice towards the use of Fracture Risk Assessment Tool (FRAX).

As shown in Fig. 3, barriers that were reported by a considerable proportion of the
pharmacists in this study were lack of time (24.4%), lack of staff (29.4%), lack of space (26.9%),
lack of patients’ interest in osteoporosis prevention activities (25%) and limited collaboration with
other healthcare providers (17.5%), whereas lack of knowledge (81.9%) and need for extra charge
(76.3%) were not reported as main barriers by the majority of pharmacists. Additionally, 90% of
the pharmacists believed that osteoporosis is a serious medical condition.

Fig.3: Barriers in providing osteoporosis services among community pharmacists in Beirut.

With regard to knowledge, the majority of surveyed pharmacists were aware that smoking
(86.3%), alcoholism (73.1%), low body mass index (51.3%), carbonated drinks (85%) and high
caffeine consumption (85%) increase osteoporotic risk. Likewise, many pharmacists were
knowledgeable about the appropriate lifestyle modifications that optimize bone health, such as
weight bearing exercises (74.4%), adequate daily calcium intake of 1200mg in women above 50
years (60.6%) and vitamin D of 1000-2000IU in adults above 50 years (80%). Sixty-five percent
were familiar with the possibility of fragility fracture occurrence on long-term proton pump
inhibitor use. Additionally, 60%, 36.9% and 42.5% knew that rheumatoid arthritis, diabetes
mellitus and hyperparathyroidism increase the risk of osteoporosis, while hypothyroidism (41.9%)
is not a risk factor. In relation to preventative therapy, 75.6% were aware that estrogen therapy
prevents bone loss after menopause. The majority (91.9%) knew that long term corticosteroid use
is an indication for bone mineral density testing and 31.9% knew that low calcium intake is not
indicative to testing. Finally, the effect of benzodiazepine, antidepressants and antipsychotics on
increasing the risk of falls was known by 63.8% 33.1% and 43.8% of pharmacists, respectively
(Refer to table 2).
Published by Digital Commons @ BAU, 2022
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Table 2: Evaluation of knowledge towards osteoporosis prevention and high-risk identification among
community pharmacists in Beirut.
% answered
correctly

% answered
incorrectly

% answered
I don’t know

Weight-bearing exercise (like walking briskly, jogging/running,
stair climbing) improves bone health

119(74.4)

31(19.4)

10(6.3)

The recommended daily intake for Calcium in women above 50
years is 1200mg

97(60.6)

39(24.4)

24(15)

The recommended daily allowance for Vitamin D in adults above
50 years is 1000-2000IU

128(80)

21(13.1)

11(6.9)

Smoking is a risk factor for osteoporosis

138(86.3)

9(5.6)

13(8.1)

Alcoholism is linked to occurrence of osteoporosis

117(73.1)

16(10)

27(16.9)

Drinking carbonated drinks (like Coca Cola, Pepsi, energy drinks)
regularly increases risk of osteoporosis

136(85)

13(8.1)

11(6.9)

High caffeine intake along with low calcium intake increases the
risk of osteoporosis

136(85)

13(8.1)

11(6.9)

Low BMI is a risk factor for osteoporosis

82(51.3)

54(33.8)

24(15)

Long-term use of proton-pump inhibitors may increase the risk for
fracture

105(65.6)

20(12.5)

35(21.9)

Hormone therapy (estrogen) prevents bone loss after menopause

121(75.6)

19(11.9)

20(12.5)

Low Calcium intake is an indication for Bone Mineral Density
testing

51(31.9)

94(58.8)

15(9.4)

Patient on corticosteroid use for a long time is an indication for
Bone Mineral Density testing

147(91.9)

3(1.9)

10(6.3)

Diabetes Mellitus

59(36.9)

92(57.5)

9(5.6)

Rheumatoid Arthritis

96(60)

55(34.4)

9(5.6)

Hypothyroidism

67(41.9)

84(52.5)

9(5.6)

Hyperparathyroidism

68(42.5)

83(51.9)

9(5.6)

Antidepressants

53(33.1)

74(46.3)

33(20.6)

Antipsychotics

70(43.8)

57(35.6)

33(20.6)

Benzodiazepines

102(63.8)

25(15.6)

33(20.6)

Statement

The disease(s) that might increase risk for osteoporosis:

The drug(s) that might increase risk of fracture
from fall in osteoporotic patients:

Mean Knowledge Score (±SD)

11.83 (±2.61)

The mean knowledge score was 11.83 (±2.61) out of 19. Results of the multiple linear
regression showed that two factors corresponded to a higher knowledge score, indicated by a
significantly positive value for ß. These factors included: graduating with a pharmacy degree from
a university in Lebanon (ß =1.46, 95%CI: 0.4–2.53) and receiving postgraduate training on
osteoporosis (ß =1.18, 95%CI: 0.34–2.02) (Refer to table 3).
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Table 3: Predictors knowledge score (related to osteoporosis prevention and high-risk identification)
amongcommunity pharmacists in Beirut.
Characteristic
Age range:
< 30 years
31 – 40 years
≥ 41 years
Gender:
Male
Female
Employment status:
Employee
Pharmacy owner
Highest educational qualification attained:
Bachelors
Masters
Pharm D
Ph.D.
University graduated from:
Outside Lebanon
In Lebanon
In your university years, did you have
enough information about osteoporosis?
No
Yes
Did you receive any postgraduate training on osteoporosis?
No
Yes
Years of work experience:
1 – 7 years
8 – 10 years
Above 10 years
How long has this pharmacy been opened for?
1 –7 years
8 – 10 years
Above 10 years
*p value <0.05, **p value<0.01

β, 95% CI

Adjusted β, 95% CI

ref
0.29(-0.73,1.31)
-0.17(-1.13,0.79)

-

ref
0.74(-0.09,1.57)

-

ref
-0.63(-1.51,0.25)

-

ref
0.30(-0.72,1.32)
0.30(-0.73,1.33)
-0.50(-2.89,1.89)

-

ref
1.26(0.19,2.33)*

ref
1.46(0.4,2.53)**

ref
0.90 (-0.12,1.93)

-

ref
1.02(0.17,1.87)*

ref
1.18(0.34,2.02)**

ref
-0.79(-1.97,0.37)
-0.31(-1.21,0.59)

-

ref
0.27(-1.24,1.79)
0.59(-0.44,1.61)

-

4. DISCUSSION
Evidence suggests that community pharmacists are well-positioned for providing
preventative services due to their convenient location, frequent contact with the public and extended
opening hours(Nik et al., 2016). However, alarmingly in this study, the practices of pharmacists
related to providingosteoporosis prevention services jeopardized the efficacy of their role in health
promotion and disease prevention. For instance, the majority of pharmacists were rarely/never
involved in counseling patients on osteoporosis risk factors (57.5%), lifestyle modifications to
optimize bone health (62.5%)including advice on adequate daily calcium (58.2%) and vitamin D
intake (66.3%-sometimes). The findings were similar to studies done by Laliberté et al. (2013)
and Nik et al. (2016), however were in contrast to the Schmiedel et al. (2013) study that identified
that 48.2% of community pharmacists were actively involved in counseling patients on
osteoporosis prevention.
Another disconcerting study finding is the practices of pharmacists related to riskassessment/screening and physician referrals. Sixty three percent of pharmacists were rarely/never
involved in obtaining patient information to identify whether patients have risk factors related to
osteoporosis. In addition, 55.6% sometimes referred high-risk patients to a doctor for BMD
testing. Community pharmacists should be able to categorize patients into risk groups and play a
significantrole in identifying high-risk patients, such as in corticosteroid users. FRAX is used in
risk stratification, to select most suitable patients for BMD testing (Khan et al., 2013). However,
based on the study findings, none of the surveyed pharmacists that were aware of FRAX (20%),
used the tool to assess patients who are at risk in their practice. In comparison to study done by
Khan et al. (2013), 46% of pharmacists were aware of FRAX and 16% utilized such tool in their
practices. Studies by Alexander & Mager (2019) and Yousuf et al. (2019) also identified a lack of
Published by Digital Commons @ BAU, 2022
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involvement of community pharmacists in osteoporosis screening. In this case, many patients at
risk or with osteoporosis are not educated on the steps they can take to prevent or minimize its
impact on health increasing the risk of morbidity, mortality and health-care costs associated with
osteoporosis. According to the American Pharmacists Association, pharmacists should engage in
public health education and provide services aimed at promoting health and preventing disease as
it is linked directly to improving patient outcomes and health system efficiency. Pharmacists
should also contribute in reducing the risk of falls, however in this study, the majority were
scarcely involved in providing such services (55.1-59.4%).
With regard to knowledge, the majority of pharmacists answered correctly the questions
related to osteoporosis risk factors, healthy lifestyle habits along with the therapies used for
prevention. However, a sizable proportion had significant knowledge gaps in the diseases
associated with osteoporosis. For instance, 60% of pharmacists were aware that rheumatoid
arthritis increases osteoporosis risk, whereas only 36.9% and 42.5% knew that diabetes mellitus
and hyperparathyroidism also intensify such possibility while hypothyroidism (41.9%) does not. A
studydone by Fogelman et al. (2016) also revealed that only 8% of surveyed participants gave
correct responses to all of these diseases. Additionally, pharmacists in this study had knowledge
gaps regarding the indications for BMD testing. The minority of pharmacists (31.9%) knew that
low calcium intake is not indicative for testing as opposed to long-term corticosteroid use (91.9%).
In comparison to a study by Al-Musa et al. (2013), 87.9% of health-care professionals had good
to excellent knowledge regarding BMD indications. Finally, pharmacists in this study showed
varying degrees of knowledge on the medications associated with increased risk of falls
(benzodiazepines, antidepressants and antipsychotics as 63.8% 33.1% and 43.8% respectively). The
results were similarto another study by Akande-Sholabi et al. (2020) where 89.3% of pharmacists
had unsatisfactory knowledge on classes of medications associated with falls.
According to the study findings, receiving postgraduate training on osteoporosis and
obtainingthe pharmacy degree from a university in Lebanon were significantly associated with
better knowledge. Therefore, continuous educational programs on osteoporosis prevention and
high-risk patient identification are strategies that the MoPH by working collaboratively with the
OPL can provide, in order to increase the knowledge, awareness and improve the health-care
services providedby community pharmacists. Moreover, foreign trained pharmacists should have
additional training to be more familiar with the community services provided regarding
osteoporosis and the health-care system in Lebanon.
The results of this study showed that a considerable proportion of pharmacists agreed that
thelack of time, staff, space, patients’ interest in prevention activities along with limited interprofessional collaboration were common barriers to providing osteoporosis services. A study by
Alameddine et al. (2020) identified that Lebanese pharmacists are facing multiple challenges when
practicing the pharmacy profession. Recommendations proposed to overcome the staff barrier
included workforce optimization and improving the working conditions by concerned
stakeholders in order to give more time for pharmacists to practice their professional roles and
engage in patient counseling. Additionally, in this study, the lack of patients’ interest in prevention
activities points atthe urging need for pharmacists to increase public awareness on osteoporosis
and the consequences for lack of prevention. On the other hand, pharmacists themselves can be
barriers to their expandingroles and implementation of disease prevention services (Nik et al.,
2016). A study by El Bizri & Dimassi (2019) identified that the majority of Lebanese pharmacists
perceived themselves as medicine experts but only 18.4 % and 9.7% perceived themselves as
patient counselors and health promoters addressing the need that pharmacists should have a better
understanding of their roles in the healthcare system.
The current study has limitations such as lack of generalizability since it was conducted in
Beirutand may hide the practices, barriers and knowledge of community pharmacists in other
Lebanese regions. Additionally, a study to assess pharmacists’ perception of their role in
osteoporosis prevention and high-risk identification would have to be conducted, the
misconception of the pharmacists in this regard has implicated effect on the results of the current
study and may reflect onthe role of pharmacists in this regard.
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5. CONCLUSION
The study findings provided important insights on the practices, barriers and knowledge of
community pharmacists regarding osteoporosis prevention and high-risk identification. The
majority of pharmacists were rarely/never involved in counseling patients on osteoporosis risk
factors, healthy lifestyle habits as well as engaging in risk-assessment, screening and physician
referrals (sometimes). Pharmacists were knowledgeable about osteoporosis prevention however
had important gaps in the diseases that increase osteoporosis risk as well as in FRAX tool,
indications that require BMD testing and increased risk of fall medications. Significant predictors
of better knowledge were receiving postgraduate training on osteoporosis and earning the
pharmacy degree from a university in Lebanon. Barriers to providing osteoporosis services
included lack of time, staff, space, patients’ interest in prevention activities and limited interprofessional collaboration.
Therefore, continuous educational programs on osteoporosis prevention and high-risk
patient identification are strategies that the MoPH by working collaboratively with the OPL can
provide, in order to increase the knowledge, awareness and improve the health-care services
provided by community pharmacists. Moreover, pharmacy schools in Lebanon should revise their
curricula to ensure proper education and training of pharmacy students on the topic involving
osteoporosis. This is necessary to enhance the public health aspect of the profession.
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